Metastatic Breast Cancer
Conditions
Keywords
Breast cancer, PTC299, VEGF, Angiogenesis, Post-transcriptional control, Aromatase inhibitors
Brief summary
Formation of new blood vessels (angiogenesis) is important for tumor growth in metastatic breast cancer. It is known that tumors make a protein called vascular endothelial growth factor (VEGF) and there are higher levels of VEGF in the tumors and blood of many women with metastatic breast cancer. VEGF stimulates the formation of blood vessels that supply the tumor with nutrients and oxygen. PTC299 is an oral drug that has been shown to decrease production of VEGF in animal models of human cancer. In these animal models, oral PTC299 administration decreases VEGF levels in the tumor and in the bloodstream, decreases blood vessel numbers in the tumor, and significantly slows or halts tumor growth. Safety studies in research animals indicate good tolerability at doses and drug levels that are higher than those planned for the clinical studies. Results from Phase 1a studies in healthy volunteers indicate that PTC299 achieves levels of PTC299 in the bloodstream that are known to be active in animal models of human cancer. This Phase 1b study is designed to test the hypothesis that PTC299 will be tolerable and will show evidence of VEGF reduction and antitumor activity when administered orally in combination with anastrozole (Arimidex®), letrozole (Femara®), or exemestane (Aromasin®) to women with metastatic breast cancer.
Detailed description
The study will be conducted in 2 stages. In Stage 1 of the study, successive groups of 3 to 6 patients will receive progressively higher PTC299 dose levels; in this stage, treatment will be given in repeated 6-week cycles consisting of 4 weeks of oral PTC299 twice per day followed by a 2-week, no-drug period. During Stage 2, study candidates must be women with natural or induced suppression of ovarian function to post-menopausal levels who are receiving or are candidates for hormonal therapy. These subjects will receive continuous administration of PTC299, 100 mg/dose BID, in repeated 6-week cycles in combination with continuous administration of one of 3 hormonal agents. All planned PTC299 dose levels in all stages are expected to achieve circulating blood levels of PTC299 known to be active in animal models of human cancer. Treatment for each patient can continue as long as the therapy appears to be safely offering tumor control to that patient. Up to 36 evaluable patients will be accrued across both stages.
Interventions
DRUGPTC299
PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
Sponsors
United States Department of Defense
PTC Therapeutics
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Major Eligibility Criteria: 1. Female sex. 2. Age ≥18 years. 3. Body weight 40-100 kg. 4. ECOG performance status of 0 or 1. 5. Histologically or cytologically confirmed adenocarcinoma of the breast. 6. Presence of metastatic disease not amenable to surgery, radiation therapy, or chemoradiotherapy with curative intent. 7. No active second metastatic malignancy other than breast cancer. 8. No unstable brain or leptomeningeal disease. 9. Discontinuation of other therapies (except for anastrozole, letrozole, or exemestane) for the treatment of breast cancer and resolution of any acute toxic effects of prior therapies. 10. Adequate bone marrow, liver, and kidney function. 11. No uncontrolled hypertension, major bleeding, HIV infection or recent acute cardiovascular event. 12. If sexually active and not postmenopausal or surgically sterile, willingness to abstain from sexual intercourse or employ an effective barrier method of contraception during the study drug administration and follow-up periods. 13. No pregnancy or breast-feeding. 14. Willingness and ability to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures, and study restrictions. 15. Willingness to provide informed consent. In addition to the criteria noted above, Stage 2 subjects must also have natural or induced suppression of ovarian function to post-menopausal levels and be receiving or be a candidate for hormonal therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Tolerated Dose (MTD) within the tested dose range. | 6 Weeks |
Secondary
| Measure | Time frame |
|---|---|
| Study drug compliance | 6 Weeks |
| Pharmacokinetics | 6 Weeks |
| Circulating angiogenic markers | 6 Weeks |
| Overall safety profile | 6 Weeks |
| Tumor metabolism as assessed by fluorodeoxyglucose positron emission tomography (FDG-PET) | 6 Weeks |
| Antitumor activity as assessed by computed tomography (CT) scans and tumor markers | 6 Weeks |
| Tumor perfusion as assessed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) | 6 Weeks |
Countries
United States
Outcome results
None listed